About Zinc finger protein 578
Zinc finger protein 578 (ZNF578) is a protein
from Homo sapiens identified by UniProt accession
Q96N58, 590 residues long.
MolForge cross-references it against 0 known binders and
8 disease associations.
Target properties
| Protein name | Zinc finger protein 578 |
| UniProt accession | Q96N58 |
| Gene | ZNF578 |
| Organism | Homo sapiens |
| Length | 590 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (8)
Diseases linked to this target (Open Targets).
- vitamin D measurement · score 0.05
- Down syndrome · score 0.04
- Ataxia-telangiectasia · score 0.01
- Leishmaniasis · score 0.01
- Sepsis · score 0.00
- neoplasm · score 0.00
- cancer · score 0.00
- Crohn's disease · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96N58-F1 | alphafold | PREDICTED | 65.01 | — |
Amino-acid sequence (590 residues)
MLHEEAAQKR KGKEPGMALP QGRLTFRDVA IEFSLAEWKF LNPAQRALYR EVMLENYRNL EAVDISSKRM MKEVLSTGQG NTEVIHTGML QRHESYHTGD FCFQEIEKDI HDFEFQSQKD ERNGHEASMP KIKELMGSTD RHDQRHAGNK PIKDQLGLSF HLHLPELHIF QPEEKIANQV EKSVNDASSI STSQRISCRP ETHTPNNYGN NFFHSSLLTQ KQEVHMREKS FQCNETGEAF NCSSFVRKHQ IIHLGEKQYK FDICGKVFNE KRYLARHRRC HTSEKPYKCN ECGKSFSYKS SLTCHRRCHT GEKPYKCNEC GKSFSYKSSL TCHHRCHTGE KPYKCNECGK SFSYKSSLRC HRRLHTGIKP YKCNECGKMF GQNSTLVIHK AIHTGEKPYK CNECGKAFNQ QSHLSRHHRL HTGEKPYKCN DCGKAFIHQS SLARHHRLHT GEKSYKCEEC DRVFSQKSNL ERHKIIHTGE KPYKCNECHK TFSHRSSLPC HRRLHSGEKP YKCNECGKTF NVQSHLSRHH RLHTGEKPYK CKVCDKAFMC HSYLANHTRI HSGEKPYKCN ECGKAHNHLI DSSIKPCMSS
Explore Zinc finger protein 578 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets